Bioanalytical Assay Development and Validation for the Pharmacokinetic Study of GMC1, a Novel FKBP52 Co-chaperone Inhibitor for Castration Resistant Prostate Cancer

Background: GMC1 (2-(1H-benzimidazol-2-ylsulfanyl)-N-[(Z)-(4-methoxyphenyl) methylideneamino] acetamide) effectively inhibits androgen receptor function by binding directly to FKBP52. This is a novel mechanism for the treatment of castration resistant prostate cancer (CRPC). Methods: an LC-MS/MS met...

Descripción completa

Detalles Bibliográficos
Autores principales: Ekpenyong, Oscar, Cooper, Candace, Ma, Jing, Guy, Naihsuan C., Payan, Ashley N., Ban, Fuqiang, Cherkasov, Artem, Cox, Marc B., Liang, Dong, Xie, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698315/
https://www.ncbi.nlm.nih.gov/pubmed/33202977
http://dx.doi.org/10.3390/ph13110386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698315/
https://www.ncbi.nlm.nih.gov/pubmed/33202977
http://dx.doi.org/10.3390/ph13110386

Ejemplares similares